CryoCath/Endocare Deal Aimed At Minimally Invasive Cardiac Surgery Market
This article was originally published in The Gray Sheet
Executive Summary
CryoCath anticipates that its five-year exclusive global supply and market access agreement with Endocare will allow for the development of a cryoablation device that can be used in keyhole surgery.
You may also be interested in...
Endocare Cryocare
Minimally-invasive cryosurgical system gains 510(k) clearance for "keyhole" thoracoscopic cardiac tissue ablation procedures to treat arrhythmias. The clearance opens the door for "a new generation of devices currently under development that treat certain cardiac conditions in a less invasive fashion" under a September 2001 strategic alliance with CryoCath Technologies (1"The Gray Sheet" Oct. 1, 2001, p. 30)...
Endocare Cryocare
Minimally-invasive cryosurgical system gains 510(k) clearance for "keyhole" thoracoscopic cardiac tissue ablation procedures to treat arrhythmias. The clearance opens the door for "a new generation of devices currently under development that treat certain cardiac conditions in a less invasive fashion" under a September 2001 strategic alliance with CryoCath Technologies (1"The Gray Sheet" Oct. 1, 2001, p. 30)...
Endocare Gains Clearance For Benign Breast Tumor Therapy; Malignant Next
Endocare will follow up its FDA 510(k) clearance of the Visica minimally invasive cryoablation system for benign breast tumors with a submission for malignant tumors.